MSS

Study/research: Using seroprevalence of Neisseria meningitidis serogroups A and X to advance introduction of conjugate Meningococcal vaccines in Ethiopia

PI/PIS: Dr. Joe Oundo/Lemma Demissie

Lead Institution: Haramaya University, London School of Hygiene and Tropical Medicine, and Ethiopian Public Health

Implementation Year: 2022-2023

Status of the project: In Progress

Funder: VactiVAC  

Project Summary

The main objectives of this study is to describe the prevalence of antibodies to Meningococcal serogroup A and X in two areas of Ethiopia with differing meningitis epidemiology; To model waning of population immunity to Meningococcus serogroup A, both in terms of accumulated unvaccinated individuals, and immune waning among mass-campaign recipients, to predict the risk of outbreaks of MenA across Ethiopia in the absence of further vaccination; and To determine factors associated with seroprevalence of Meningococcal serogroups A and X.

We will perform two cross sectional surveys among residents of the Bambasi-HDSS site in western Ethiopia and the Kersa-HDSS site in eastern Ethiopia and from November 1, 2022, to May 31st, 2023. We will enroll 1000 randomly from each HDSSs which is similar sample size with meningococcal carriage study and likely to provide adequate power for the analyses envisaged. The age will be stratified to four groups as 0-8 years, 8-17 years, 18-29 years, and 30 years.